More than 25 years of experience in pharmaceutical business development brings Simon Dew to Macomics Ltd. (Edinburgh and Cambridge, UK). He took over the newly created position of Chief Business Officer (CBO) in June.

Dew is currently on the Business Development Board of Sunstone Capital, a Danish Venture Capital Company and, most recently served as CBO at ReNeuron Group. His career also includes significant roles at Gyroscope Therapeutics, Astellas Pharmaceuticals, IQVIA, Parexel, Phytopharm plc, and GSK/SB, where he demonstrated exceptional expertise in business development, corporate strategy, and operational leadership. He has a BSc in Pharmacy and has completed the INSEAD Managing Partnerships and Strategic Alliances and M&A Executive Program.

Dr Stephen Myatt, CEO of Macomics said, “I am delighted to welcome Simon to the company. Business development is a critical role to our leadership team and Simon’s extensive experience and successful track record in the biotech and pharmaceutical industry will be invaluable as we continue to advance our macrophage-targeted therapies and expand our strategic partnerships. Macrophages are key to multiple diseases of high unmet medical need, including as key mediators of solid tumour immunosuppression and pathological inflammation in chronic inflammatory disorders.”